149 related articles for article (PubMed ID: 28057740)
1. Dasatinib and allogeneic stem cell transplantation enable sustained response in an elderly patient with
Frech M; Jehn LB; Stabla K; Mielke S; Steffen B; Einsele H; Metzelder SK; Neubauer A
Haematologica; 2017 Apr; 102(4):e160-e162. PubMed ID: 28057740
[No Abstract] [Full Text] [Related]
2. RCSD1-ABL1-positive B lymphoblastic leukemia is sensitive to dexamethasone and tyrosine kinase inhibitors and rapidly evolves clonally by chromosomal translocations.
Inokuchi K; Wakita S; Hirakawa T; Tamai H; Yokose N; Yamaguchi H; Dan K
Int J Hematol; 2011 Sep; 94(3):255-260. PubMed ID: 21863287
[TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia associated with RCSD1-ABL1 novel fusion gene has a distinct gene expression profile from BCR-ABL1 fusion.
De Braekeleer E; Douet-Guilbert N; Guardiola P; Rowe D; Mustjoki S; Zamecnikova A; Al Bahar S; Jaramillo G; Berthou C; Bown N; Porkka K; Ochoa C; De Braekeleer M
Leukemia; 2013 Jun; 27(6):1422-4. PubMed ID: 23168614
[No Abstract] [Full Text] [Related]
4. t(1;9)(p34;q34)/SFPQ-ABL1 Fusion in a Patient with Ph-Like Common B-Cell Acute Lymphoblastic Leukemia.
Sheng G; Zeng Z; Pan J; Wang Q; Yao H; Wen L; Ma L; Wu D; Chen S
Acta Haematol; 2017; 137(1):40-43. PubMed ID: 27894117
[No Abstract] [Full Text] [Related]
5. SNX2-ABL1-positive acute lymphoblastic leukemia possibly has a poor prognosis.
Mu Q; Guo L; Hu Y; Sheng L; Zhang Y; Wu N; Chen Y; Shi C; Shi S; Wu Y; Ouyang G
Leuk Lymphoma; 2017 Sep; 58(9):1-3. PubMed ID: 28278724
[No Abstract] [Full Text] [Related]
6. Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.
Hu T; Ciccarelli BT
Leuk Res; 2014 Dec; 38(12):1399-400. PubMed ID: 25449686
[No Abstract] [Full Text] [Related]
7. Characteristics of patients with development of large granular lymphocyte expansion among dasatinib-treated patients with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic stem cell transplantation.
Ito Y; Miyamoto T; Kamimura T; Aoki K; Henzan H; Aoki T; Shiratsuchi M; Kato K; Nagafuji K; Ogawa R; Eto T; Iwasaki H; Akashi K
Clin Lymphoma Myeloma Leuk; 2015 Mar; 15(3):e47-54. PubMed ID: 25445469
[TBL] [Abstract][Full Text] [Related]
8. A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia.
De Braekeleer E; Douet-Guilbert N; Le Bris MJ; Berthou C; Morel F; De Braekeleer M
Leukemia; 2007 Oct; 21(10):2220-1. PubMed ID: 17541395
[No Abstract] [Full Text] [Related]
9. Imatinib-induced long-term remission in a relapsed RCSD1-ABL1-positive acute lymphoblastic leukemia.
Perwein T; Strehl S; König M; Lackner H; Panzer-Grümayer R; Mann G; Attarbaschi A; Urban EC; Haas OA
Haematologica; 2016 Aug; 101(8):e332-5. PubMed ID: 27125982
[No Abstract] [Full Text] [Related]
10. Response to single agent dasatinib post allogeneic transplant in B-cell acute lymphoblastic leukemia with
Aldoss I; Pullarkat V
Leuk Lymphoma; 2019 Nov; 60(11):2832-2834. PubMed ID: 31014138
[No Abstract] [Full Text] [Related]
11. Successful treatment of the first adult case of ZMIZ1::ABL1-positive B cell lymphoblastic leukemia with dasatinib, chimeric antigen receptor T-cell therapy, and allogeneic hematopoietic stem cell transplantation.
Chen X; Yuan L; Ma X; Cao P; Wang F; Zhang Y; Chen J; Zhang X; Zhao Y; Liu H
Cancer Genet; 2024 Jun; 284-285():16-19. PubMed ID: 38503133
[No Abstract] [Full Text] [Related]
12. SFPQ-ABL1-positive B-cell precursor acute lymphoblastic leukemias.
Biloglav A; Olsson-Arvidsson L; Theander J; Behrendtz M; Castor A; Johansson B
Genes Chromosomes Cancer; 2020 Sep; 59(9):540-543. PubMed ID: 32306475
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib Use and Risk of Cytomegalovirus Reactivation After Allogeneic Hematopoietic-Cell Transplantation.
Prestes DP; Arbona E; Nevett-Fernandez A; Woolley AE; Ho VT; Koo S; Baden LR; Koreth J; Hammond SP; Issa NC; Marty FM
Clin Infect Dis; 2017 Aug; 65(3):510-513. PubMed ID: 28419210
[TBL] [Abstract][Full Text] [Related]
14. A novel dasatinib-sensitive RCSD1-ABL1 fusion transcript in chemotherapy-refractory adult pre-B lymphoblastic leukemia with t(1;9)(q24;q34).
Mustjoki S; Hernesniemi S; Rauhala A; Kähkönen M; Almqvist A; Lundán T; Porkka K
Haematologica; 2009 Oct; 94(10):1469-71. PubMed ID: 19794096
[No Abstract] [Full Text] [Related]
15. Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.
Millot F; Cividin M; Brizard F; Chomel JC; Méchinaud F; Guilhot F
Pediatr Blood Cancer; 2009 Jul; 52(7):891-2. PubMed ID: 19202569
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib as an investigational drug for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia in adults.
Brattås MK; Reikvam H; Tvedt THA; Bruserud Ø
Expert Opin Investig Drugs; 2019 May; 28(5):411-420. PubMed ID: 30916583
[TBL] [Abstract][Full Text] [Related]
17. Poor responses to tyrosine kinase inhibitors in a child with precursor B-cell acute lymphoblastic leukemia with SNX2-ABL1 chimeric transcript.
Masuzawa A; Kiyotani C; Osumi T; Shioda Y; Iijima K; Tomita O; Nakabayashi K; Oboki K; Yasuda K; Sakamoto H; Ichikawa H; Hata K; Yoshida T; Matsumoto K; Kiyokawa N; Mori T
Eur J Haematol; 2014 Mar; 92(3):263-7. PubMed ID: 24215620
[TBL] [Abstract][Full Text] [Related]
18. Identification of FOXP1 and SNX2 as novel ABL1 fusion partners in acute lymphoblastic leukaemia.
Ernst T; Score J; Deininger M; Hidalgo-Curtis C; Lackie P; Ershler WB; Goldman JM; Cross NC; Grand F
Br J Haematol; 2011 Apr; 153(1):43-6. PubMed ID: 21391972
[TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.
Brissot E; Labopin M; Beckers MM; Socié G; Rambaldi A; Volin L; Finke J; Lenhoff S; Kröger N; Ossenkoppele GJ; Craddock CF; Yakoub-Agha I; Gürman G; Russell NH; Aljurf M; Potter MN; Nagler A; Ottmann O; Cornelissen JJ; Esteve J; Mohty M
Haematologica; 2015 Mar; 100(3):392-9. PubMed ID: 25527562
[TBL] [Abstract][Full Text] [Related]
20. Does Post-Transplant Maintenance Therapy With Tyrosine Kinase Inhibitors Improve Outcomes of Patients With High-Risk Philadelphia Chromosome-Positive Leukemia?
DeFilipp Z; Langston AA; Chen Z; Zhang C; Arellano ML; El Rassi F; Flowers CR; Kota VK; Al-Kadhimi Z; Veldman R; Jillella AP; Lonial S; Waller EK; Khoury HJ
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16(8):466-471.e1. PubMed ID: 27297665
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
